Polypharmacotherapy: the Use of Artificial Intelligence to Reduce Risk of Adverse Drug Reactions (Review)

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Artificial intelligence (AI) in healthcare can be used to solve a wide range of tasks, such as diagnosis, treatment and self-monitoring of patients. This review is devoted to the problem of polypharmacotherapy, the development of adverse drug reactions as a consequence of it and the use of AI in this field. AI allows to analyze drug interactions, identify possible adverse drug reactions and suggest optimal combinations of drugs and drug regimen. The use of clinical decision support systems, which are developed in various countries, has shown improved efficiency of the doctor’s work and increased patient’s safety with the help of AI. The use of AI in polypharmacotherapy requires further research and development to improve software products that would allow evaluating not only paired, but also multiple drug interactions.

Full Text

Restricted Access

About the authors

Valery V. Beregovykh

Russian Academy of Sciences

Email: beregovykh@ramn.ru
ORCID iD: 0000-0002-0210-4570
SPIN-code: 5940-7554

PhD in Technical Sciences, Professor, Academician of the RAS

Россия, Moscow

Vladimir I. Panteleev

Plekhanov Russian University of Economics

Author for correspondence.
Email: vpantel@mail.ru
ORCID iD: 0000-0002-1575-1267
SPIN-code: 4095-8670

MD, PhD

Россия, Moscow

Nikolay L. Shimanovsky

Plekhanov Russian University of Economics

Email: shimann@yandex.ru
ORCID iD: 0000-0001-8887-4420
SPIN-code: 5232-8230

MD, PhD, Professor, Corresponding Member of the RAS

Россия, Moscow

References

  1. Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В., и др. Полифармация: определение, влияние на исходы, необходимость коррекции // Рациональная фармакотерапия в кардиологии. — 2023. — Т. 19. — № 3. — С. 254–263. [Martsevich SYu, Kutishenko NP, Lukina YuV, et al. Polypharmacy: definition, impact on outcomes, need for correction. Rational Pharmacotherapy in Cardiology. 2023;19(3):254–263. (In Russ.)] doi: https://doi.org/10.20996/1819-6446-2023-2924
  2. Akyon SH, Akyon FC, Yilmaz TE. Artificial intelligence-supported web application design and development for reducing polypharmacy side effects and supporting rational drug use in geriatric patients. Front Med (Lausanne). 2023;10:1029198. doi: https://doi.org/10.3389/fmed.2023.1029198
  3. Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32–38.
  4. Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28(2):159–172. doi: https://doi.org/10.1016/j.cger.2012.01.001
  5. Pesante-Pinto JL. Clinical Pharmacology and the Risks of Polypharmacy in the Geriatric Patient. Phys Med Rehabil Clin N Am. 2017;28(4):739–746. doi: https://doi.org/10.1016/j.pmr.2017.06.007
  6. Gómez C, Vega-Quiroga S, Bermejo-Pareja F, et al. Polypharmacy in the Elderly: A Marker of Increased Risk of Mortality in a Population-Based Prospective Study (NEDICES). Gerontology. 2015;61(4):301–309. doi: https://doi.org/10.1159/000365328
  7. Katzke VA, Bajracharya R, Nasser MI, et al. Number of medically prescribed pharmaceutical agents as predictor of mortality risk: a longitudinal, time-variable analysis in the EPIC-Heidelberg cohort. Sci Rep. 2024;14(1):106. doi: https://doi.org/10.1038/s41598-023-50487-5
  8. Kwak MJ, Chang M, Chiadika S, et al. Healthcare Expenditure Associated with Polypharmacy in Older Adults with Cardiovascular Diseases. Am J Cardiol. 2022;169:156–158. doi: https://doi.org/10.1016/j.amjcard.2022.01.012
  9. Bezerra HS, Brasileiro Costa AL, Pinto RS, et al. Economic impact of pharmaceutical services on polymedicated patients: A systematic review. Res Social Adm Pharm. 2022;18(9):3492–3500. doi: https://doi.org/10.1016/j.sapharm.2022.03.005
  10. Zhou D, Chen Z, Tian F. Deprescribing Interventions for Older Patients: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2023;24(11):1718–1725. doi: https://doi.org/10.1016/j.jamda.2023.07.016
  11. Mangin D, Lamarche L, Agarwal G, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 2021;22(1):746. doi: https://doi.org/10.1186/s13063-021-05685-9
  12. The 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi: https://doi.org/10.1111/jgs.18372
  13. O’Mahony D, Cherubini A, Guiteras AR, et al. Correction: STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):633. doi: https://doi.org/10.1007/s41999-023-00812-y
  14. Bahat G, Ilhan B, Erdogan T, et al. Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START. Eur Geriatr Med. 2020;11(3):491–498. doi: https://doi.org/10.1007/s41999-020-00297-z
  15. Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861–875. doi: https://doi.org/10.1007/s00228-015-1860-9
  16. Mühlbauer B. The New PRISCUS List. Dtsch Arztebl Int. 2023;120(1–2):1–2. doi: https://doi.org/10.3238/arztebl.m2022.0408
  17. Pazan F, Weiss C, Wehling M; FORTA. Correction to: The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults. Drugs Aging. 2022;39(6):485. doi: https://doi.org/10.1007/s40266-022-00954-x
  18. Fastbom J, Johnell K. National indicators for quality of drug therapy in older persons: the Swedish experience from the first 10 years. Drugs Aging. 2015;32(3):189–199. doi: https://doi.org/10.1007/s40266-015-0242-4
  19. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(9):1825–1832.
  20. Barry PJ, Gallagher P, Ryan C, et al. START (screening tool to alert doctors to the right treatment) — an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36(6):632–638. doi: https://doi.org/10.1093/ageing/afm118
  21. Сычев Д.А., Отделёнов В.А., Краснова Н.М., и др. Полипрагмазия: взгляд клинического фармаколога // Терапевтический архив. — 2016. — Т. 88. — № 12. — С. 94–102. [Sychev DA, Otdelеnov VA, Krasnova NM, et al. Polypragmasy: A clinical pharmacologist’s view. Terapevticheskii Arkhiv. 2016;88(12):94–102. (In Russ.)] doi: https://doi.org/10.17116/terarkh2016881294-102
  22. Wallerstedt SM, Svensson SA, Lönnbro J, et al. Performance of 3 Sets of Criteria for Potentially Inappropriate Prescribing in Older People to Identify Inadequate Drug Treatment. JAMA Netw Open. 2022;5(10):e2236757. doi: https://doi.org/10.1001/jamanetworkopen.2022.36757
  23. Martins C, Godycki-Cwirko M, Heleno B, et al. Quaternary prevention: reviewing the concept. Eur J Gen Pract. 2018;24(1):106–111. doi: https://doi.org/10.1080/13814788.2017.1422177
  24. Остроумова О.Д., Черняева М.С., Сычев Д.А. Депрескрайбинг антигипертензивных препаратов у пациентов старших возрастных групп // Рациональная фармакотерапия в кардиологии. — 2020. — Т. 16. — № 1. — С. 82–93. [Ostroumova OD, Cherniaeva MS, Sychev DA. Deprescribing Antihypertensive Drugs in Patients of Older Age Groups. Rational Pharmacotherapy in Cardiology. 2020;16(1):82–93. (In Russ.)] doi: https://doi.org/10.20996/1819-6446-2020-02-14
  25. Veronese N, Gallo U, Boccardi V, et al. Efficacy of deprescribing on health outcomes: An umbrella review of systematic reviews with meta-analysis of randomized controlled trials. Ageing Res Rev. 2024:95:102237. doi: https://doi.org/10.1016/j.arr.2024.102237
  26. Ibrahim K, Cox NJ, Stevenson JM, et al. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 2021;21(1):258. doi: https://doi.org/10.1186/s12877-021-02208-8
  27. Panch T, Szolovits P, Atun R. Artificial intelligence, machine learning and health systems. J Glob Health. 2018;8(2):020303. doi: https://doi.org/10.7189/jogh.08.020303
  28. Chew HSJ, Achananuparp P. Perceptions and Needs of Artificial Intelligence in Health Care to Increase Adoption: Scoping Review. J Med Internet Res. 2022;24(1):e32939. doi: https://doi.org/10.2196/32939
  29. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi: https://doi.org/10.1038/s41591-018-0300-7
  30. Vo TH, Nguyen NTK, Kha QH, et al. On the road to explainable AI in drug-drug interactions prediction: A systematic review. Comput Struct Biotechnol J. 2022;20:2112–2123. doi: https://doi.org/10.1016/j.csbj.2022.04.021
  31. Farmantek. Farmantek rational drug use assistant. 2024. Available from: http://farmantek.herokuapp.com/
  32. Medscape. Drug interaction checker. 2024. Available from: https://reference.medscape.com/drug-interactionchecker
  33. WebMD. Drug interaction checker. 2024. Available from: https://www.webmd.com/interaction-checker/default.html
  34. Vademecum Online. Vademecum Api. 2024. Available from: https://www.vademecumonline.com.tr/site/vademecum-api
  35. Xiong, G, Yang, Z, Yi, J, et al. DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200–D1207. doi: https://doi.org/10.1093/nar/gkab880
  36. UpToDate. Lexicomp drug interaction checker. 2024. Available from: https://www.uptodate.com/contents/search
  37. Computational Biologyand Drug Design Group. DDInter. 2024. Available from: http://ddinter.scbdd.com/
  38. Niehoff KM, Rajeevan N, Charpentier PA, et al. Development of the tool to reduce inappropriate medications (TRIM): a clinical decision support system to improve medication prescribing for older adults. Pharmacotherapy. 2016;36(6):694–701. doi: https://doi.org/10.1002/phar.1751
  39. MedStopper web site. MedStopper. 2024. Available from: http://www.medstopper.com
  40. Canadian Deprescribing Network web site. Canadian Deprescribing network. 2024. Available from: https://www.deprescribingnetwork.ca/
  41. Community Interest Company. Prescqipp. 2024. Available from: https://www.prescqipp.info/
  42. Working Towards Safer Prescribing. MedSafer. 2024. Available from: https://www.medsafer.org/
  43. Шимановский Н.Л., Шегай М.М., Роик Р.О. Можно ли снизить риск развития нежелательных эффектов лекарственных средств с помощью компьютерных технологий (обзор) // Проблемы социальной гигиены, здравоохранения и истории медицины. — 2023. — Т. 31. — № 4. — С. 605–612. [Shimanovskiy NL, Shegai MM, Roik RO. Is possible to decrease the risk of development of undesirable effects of medications applying computer technologies? (a review). Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2023;31(4):605–612. (In Russ.)] doi: http://dx.doi.org/10.32687/0869-866X-2023-31-4-605-612
  44. Судаков В.А., Шимановский Н.Л. Снижение риска развития нежелательных эффектов лекарственных средств с помощью искусственного интеллекта // Экспериментальная и клиническая фармакология. — 2023. — Т. 86. — № 11s. — С. 141. [Sudakov VA, Shimanovskij NL. Snizhenie riska razvitiya nezhelatel’nyh effektov lekarstvennyh sredstv s pomoshch’yu iskusstvennogo intellekta. Eksperimental’naya i klinicheskaya farmakologiya. 2023;86(11s):141. (In Russ.)] doi: https://doi.org/10.30906/ekf-2023-86s-141a
  45. Rieckert A, Reeves D, Altiner A, et al. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. BMJ. 2020;369:m1822. doi: https://doi.org/10.1136/bmj.m1822
  46. Doherty AS, Boland F, Moriarty F, et al. Adverse drug reactions and associated patient characteristics in older community-dwelling adults: a 6-year prospective cohort study. Br J Gen Pract. 2023;73(728):e211–e219. doi: https://doi.org/10.3399/BJGP.2022.0181
  47. Amorim WW, Passos LC, Gama RS, et al. Using a mobile application to reduce potentially inappropriate prescribing for older Brazilian adults in primary care: a triple-blind randomised clinical trial. BMC Geriatr. 2024;24(1):35. doi: https://doi.org/10.1186/s12877-023-04645-z
  48. Bakker T, Klopotowska JE, Dongelmans DA, et al. The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial. Lancet. 2024;403(10425):439–449. doi: https://doi.org/10.1016/S0140-6736(23)02465-0
  49. Segal G, Segev A, Brom A, et al. Reducing drug prescription errors and adverse drug events by application of a probabilistic, machine-learning based clinical decision support system in an inpatient setting. J Am Med Inform Assoc. 2019;26(12):1560–1565. doi: https://doi.org/10.1093/jamia/ocz135
  50. Rathore A, Sharma R, Bansal P, et al. Knowledge, attitude, and practice of medical interns and postgraduate residents on American Geriatric Society updated Beers criteria. J Educ Health Promot. 2023;12:1. doi: https://doi.org/10.4103/jehp.jehp_769_22
  51. Ильина Е.С., Богова О.Т., Савельева М.И., и др. Результаты аудита лекарственных назначений у пациентов старческого возраста с падением в условиях стационара после обучения врачей принципам рациональной фармакотерапии // Фармакология и фармакотерапия. — 2023. — № 4. — С. 20–25. [Ilyina ES, Bogova OT, Savelyeva MI, et al. Results of an audit of drug prescriptions in elderly patients with fall in a hospital after training doctors in the principles of rational pharmacotherapy. Pharmacology & Pharmacotherapy. 2023;4:20–25. (In Russ.)] doi: https://doi.org/10.46393/27132129_2023_4_20

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies